How Vertex Pharmaceuticals Stock Has Been Trading Recently

Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52 at the last close on 1 September 2026. Recent returns show mixed short term moves, with stronger performance over the past 3 months and over the past year.

Over the past year, Vertex Pharmaceuticals has combined a strong 90 day share price return of 28.10% with a 1 year total shareholder return of 39.26%. This suggests that recent price strength is building on longer term gains as the market reassesses its growth prospects and risk profile.

Compare the recent surge in Vertex Pharmaceuticals with hand picked peers by scanning 45 high quality undervalued stocks to find companies that pair solid fundamentals with recent price momentum.

Vertex Pharmaceuticals now combines a broad portfolio in serious diseases with a share price near its recent high. The key test for investors is whether this strength is already fully reflected in the valuation.

Most Popular Narrative: 2.5% Undervalued

The most followed narrative currently places Vertex Pharmaceuticals fair value at $558.68, a touch above the last close at $544.52. That small gap frames a story built on expanding franchises and a broader pipeline rather than a deep discount.

Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies, positioning the company to capture long-term growth from accelerating personalized and precision medicine adoption, supporting both revenue and long-term margin expansion.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value edges above the current price rather than sitting far higher? The narrative leans on brisk top line expansion, firmer margins and a future earnings profile that assumes a premium P/E multiple. Curious which growth and profitability paths have been baked into that model and how much depends on new therapies scaling cleanly.

Result: Fair Value of $558.68 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Vertex Pharmaceuticals still faces key risks if payer pricing tightens or if high cost R&D programs in pain, kidney, or gene editing deliver weaker than expected outcomes.

Find out about the key risks to this Vertex Pharmaceuticals narrative.

Next Steps

Sentiment around Vertex Pharmaceuticals in this article may feel cautiously optimistic, so it helps to stress test the data for yourself and move quickly while the details are fresh. To see what is driving that optimism, take a closer look at the 3 key rewards .